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Background: β1- and β2–adrenergic receptors (ARs) play distinct roles in the heart, e.g. β1AR is pro-contractile and
pro-apoptotic but β2AR anti-apoptotic and only weakly pro-contractile. G protein coupled receptor kinase (GRK)-2
desensitizes and opposes βAR pro-contractile signaling by phosphorylating the receptor and inducing beta-arrestin
(βarr) binding. We posited herein that GRK2 blockade might enhance the pro-contractile signaling of the β2AR
subtype in the heart. We tested the effects of cardiac-targeted GRK2 inhibition in vivo exclusively on β2AR signaling
under normal conditions and in heart failure (HF).
Results: We crossed β1AR knockout (B1KO) mice with cardiac-specific transgenic mice expressing the βARKct, a
known GRK2 inhibitor, and studied the offspring under normal conditions and in post-myocardial infarction (MI).
βARKct expression in vivo proved essential for β2AR-dependent contractile function, as β2AR stimulation with
isoproterenol fails to increase contractility in either healthy or post-MI B1KO mice and it only does so in the
presence of βARKct. The main underlying mechanism for this is blockade of the interaction of phosphodiesterase
(PDE) type 4D with the cardiac β2AR, which is normally mediated by the actions of GRK2 and βarrs on the receptor.
The molecular “brake” that PDE4D poses on β2AR signaling to contractility stimulation is thus “released”. Regarding
the other beneficial functions of cardiac β2AR, βARKct increased overall survival of the post-MI B1KO mice
progressing to HF, via a decrease in cardiac apoptosis and an increase in wound healing-associated inflammation
early (at 24 hrs) post-MI. However, these effects disappear by 4 weeks post-MI, and, in their place, upregulation of
the other major GRK in the heart, GRK5, is observed.
Conclusions: GRK2 inhibition in vivo with βARKct is absolutely essential for cardiac β2AR pro-contractile signaling
and function. In addition, β2AR anti-apoptotic signaling in post-MI HF is augmented by βARKct, although this effect
is short-lived.
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Despite recent advances in prevention and management
of heart disease, death due to post-myocardial infarction
(MI) heart failure (HF) continues to rise and new treat-
ments are needed [1]. β1- and β2–adrenergic receptors
(ARs) are the main stimulatory receptors of cardiac
function but are now known to play clearly distinct roles
in cardiac physiology and pathology [2-5]. For instance,
cardiomyocyte contraction is readily stimulated by
β1ARs but not β2ARs and β1AR signaling is generally
considered pro-apoptotic whereas β2AR signaling anti-
apoptotic in the heart [2-5]. These differences might be
explained by differences in the signaling complexes as-
sembled by activation of these two βARs: β1AR forms a
complex with phosphodiesterase (PDE) 4D8 directly
when inactive, and agonist binding dissociates it [6,7].
Additionally, β1AR does not readily bind the receptor
adapter proteins beta-arrestins (βarrs) following its
agonist-promoted phosphorylation by G protein coupled
receptor kinases (GRKs), the most prominent members
of which in the heart are GRK2 and −5 [8-11]. In con-
trast, β2AR recruits another PDE variant upon its agonist
activation, PDE4D5, via its interaction with βarrs follow-
ing its GRK-dependent phosphorylation [6,7,12-16]. PDE
recruitment to the receptor’s signaling complex plays a
crucial role in compartmentalizing the cyclic adenosine
monophosphate (cAMP) signal and thereby tightly
regulating βAR-stimulated contractility [7]. It has been
postulated that this PDE4D5 recruitment to the agonist-
activated cardiac β2AR poses a “brake” on the β2AR cAMP
signaling’s ability to stimulate contractility [6,7,13,15]. By
contrast, agonist-promoted dissociation of PDE from the
β1AR underlies the more “diffuse” and more powerful at
stimulating contraction signaling of this βAR subtype
[6,7]. Of note, cardiac β2AR signaling has been reported to
become more “diffuse” and decompartmentalized, i.e. to
adopt a β1AR-like signaling pattern, in a rat model of HF,
which might underlie cardiac β2AR dysfunction in
HF [17].
On the other hand, cardiac β2AR can switch its signaling
from Gs protein-mediated to Gi/o protein-mediated, which
is believed to underlie its anti-apoptotic effects and is a
feature cardiac β1ARs lack [18-24]. Finally, the interactions
of the β2AR with the βarrs, which require prior receptor
phosphorylation by GRKs, can have pleiotropic effects in
cardiac myocytes, such as inhibition of apoptosis/pro-
motion of survival by promoting extracellular signal-
regulated kinase (ERK) signaling [25] and inhibition of
inflammation by blocking the pro-inflammatory trans-
cription factor nuclear factor-kappaB (NF-κB) [26,27], a
crucial mediator of major pro-inflammatory cytokine ex-
pression, such as tumor necrosis factor-alpha (TNF-α)
and interleukin-1 and −6 (IL-1 & -6) [28-30]. These βarr-
dependent signaling effects may also play some part in thewell known and described anti-apoptotic and other benefi-
cial in post-MI HF effects of cardiac β2AR.
Cardiac GRK2 is a major negative regulator of βAR pro-
contractile signaling [8-11]. By desensitizing both β1- and
β2ARs, i.e. terminating their G protein-mediated signaling
through cAMP, it dramatically reduces cardiac inotropic
and adrenergic reserves, and since it is markedly elevated
in HF, its blockade represents an attractive therapeutic
strategy for heart disease treatment [8-11,31-35]. Given
that GRK2 can block the pro-contractile and other benefi-
cial signaling of cardiac β2AR in HF, and also that its ac-
tion on β2AR induces recruitment of βarrs with all their
aforementioned myriad effects on this receptor’s signaling,
we hypothesized, in the present study, that cardiac GRK2
blockade in vivo might enhance β2AR signaling post-MI.
In order to study the effects of GRK2 blockade specifically
on this subtype’s signaling, without any interference by the
qualitatively different β1AR signaling, we utilized the β1AR
knockout (B1KO) mice [36], which we crossed with mice
overexpressing the known GRK2 inhibitor mini-gene
βARKct (or GRK2ct) specifically in cardiac myocytes [32].
After breeding the offspring to homozygosity, we studied
them both under normal conditions (i.e. healthy, sham-
operated animals) and after surgically induced MI to induce
HF. We found that GRK2 inhibition in vivo is absolutely
necessary for the β2AR to be capable of increasing contract-
ility. In addition, β2AR anti-apoptotic signaling post-MI is
augmented by βARKct, but only acutely.
Results
βARKct restores cardiac β2AR-dependent pro-contractile
signaling by reducing the interaction of PDE4D with the
receptor
We developed the hybrid transgenic line βARKct/B1KO
by crossing the B1KO mice with the βARKct transgenic
mice, which express βARKct only in cardiomyocytes.
The βARKct/B1KO’s breed normally, without any gross
abnormalities and present no overt cardiovascular or
other phenotype (data not shown). Three-month-old
male mice were chosen to undergo surgical MI in order
to induce HF and were studied alongside age-matched
male homozygous B1KO’s (without βARKct expression),
which served as the control group.
Since GRK2 is a major (negative) regulator of cardiac
βAR-dependent contractility in vivo, and the β2AR stimu-
lates contractility only very weakly, we first examined the
cardiac function parameters of these mice, both in sham
and post-MI groups. Echocardiography revealed that the
B1KO mice display significantly decreased ejection frac-
tion compared to control wild type (WT) mice, both under
normal conditions (sham groups) and at 4 weeks post-MI,
as expected since the β1AR is the major βAR subtype in
the heart stimulating contractility (Table 1) [8]. Notably,
βARKct overexpression led to significant augmentation of













Infarct size (% LV free wall) N/A N/A N/A N/A 41±1.2 42±2.2 40±2.6 43±3.0
FS (%) 41.4±1.3 48.3±2.8^ 36.7±2.6^ 41.3±2.4# 18.6±2.2 23.7±1.3+ 11.0±1.4+ 19.0±2.4*
EF (%) 72.0±1.0 78.0±2.0^ 67.0±2.4^ 72.0±2.0# 37.5±3.0 45.3±2.4+ 23.7±2.5+ 38.5±4.2*
Basal HR (min–1) 385±12 402±37 402±27 383±23 392±12 408±10 391±8 389±13
Basal LV +dP/dtmax
(mm Hg/s)
4692±363 6835±637^ 3572±287^ 4576±375# 3512±220 4900±172+ 2576±155+ 3549±231*
Basal LV –dP/dtmin
(mm Hg/s)
−4568±452 −6714±536^ −3269±296^ −4782±286# −3515±246 −4620±203+ −2592±233+ −3471±194*
Max. Iso-HR (min–1) 557±36 515±40 405±28^ 393±14^ 509±24 581±17+ 399±11+ 413±20+
Max. Iso-LV +dP/dtmax
(mm Hg/s)
8825±644 13547±476^ 3611±286^ 9041±528# 5641±431 9419±601+ 2639±139+ 5628±419*
Max. Iso-LV–dP/dtmin
(mm Hg/s)
−7210±430 −8837±491^ −3199±279^ −6344±364# −5880±303 −6948±277+ −2605±251+ −5548±382*
Cardiac parameter values of three-month-old wild type (WT, i.e. C57/B6), βARKct, B1KO and βARKct/B1KO mice measured at 4 weeks after MI or sham operation
(Sham). LV +dP/dtmax maximal first derivative of LV pressure rise, LV –dP/dtmin minimal first derivative of LV pressure fall, HR heart rate, FS, fractional shortening,
EF ejection fraction, LV Left ventricular, N/A Not applicable, Max. Iso dose: 333 ng/kg body weight. #, p<0.05, vs. B1KO-Sham; *, p<0.05, vs. B1KO-MI; ^, p<0.05,
vs. WT-Sham; +, p<0.05, vs. WT-MI; n=7 mice/group. One-way ANOVA with Bonferroni test was performed among groups. Data are presented as mean ± SEM.
Salazar et al. Cell Communication and Signaling 2013, 11:64 Page 3 of 10
http://www.biosignaling.com/content/11/1/64the ejection fraction of the B1KO mice, up to the levels of
WT mice, again both in normal and in 4 week post-MI
mice (Table 1), while, as already known from our studies
in the past [10,11,32,33], βARKct significantly augments
contractility of the WT mice, as well (Table 1). Import-
antly, when the mice underwent in vivo cardiac cathe-
terization to measure their hemodynamic responses to
isoproterenol stimulation (a standard βAR full agonist),
B1KO mice, remarkably, completely failed to show any in-
crease in contractility (as measured by the +dP/dtmax LV
pressure elevation parameter), even at the highest concen-
tration of isoproterenol challenge (Max. Iso, Table 1). In
contrast, the hybrid βARKct/B1KO mice showed very
good contractile responses to isoproterenol, both in the
sham (healthy) conditions and in post-MI HF (Table 1).
As expected, the other two mouse lines, i.e. WT and
βARKct, were responsive to βAR stimulation, with the HF
animals in these groups showing somewhat reduced re-
sponses compared to their sham counterparts and the
βARKct line displaying much more robust responses com-
pared to the WT group (Table 1). These results strongly
indicate that cardiac GRK2 is a major opposing force for
the β2AR pro-contractile function and only when its activ-
ity is blocked (e.g. in the presence of βARKct) is the car-
diac β2AR capable of promoting contractility in response
to agonist stimulation.
To identify the main signaling mechanism underlying
this dramatic effect of βARKct on cardiac β2AR-
dependent contractiity, we examined the levels of
PDE4D interaction with the β2AR in cardiac membranes
of these mice in vivo. As shown in Figures 1A and 1B,
the interaction of cardiac β2AR with both the PDE4D3
and -D5 isoforms is significantly reduced in βARKct/B1KO mouse hearts compared to control B1KO hearts,
an effect that might enable βARKct to enhance cardiac
β2AR-dependent pro-contractile signaling in vivo.
βARKct and cardiac β2AR-dependent anti-apoptotic/
inflammatory signaling
Next, we examined the impact of βARKct expression on
the other major aspect of cardiac β2AR signaling, anti-
apoptosis/cardiac survival. Post-MI βARKct/B1KO mice
display markedly better survival post-MI compared to their
B1KO counterparts (Figure 2A). Kaplan-Meier survival
curves indicated that at 4 weeks post-MI, a significant
(~70%) of βARKct/B1KO’s are still alive, compared to
only ~40% of B1KO’s at the same time point post-MI
(Figure 2A). In addition, cardiac apoptosis is found signifi-
cantly decreased very early (at 24 hrs) post-MI in the
βARKct/B1KO hearts compared to control B1KO hearts
(Figure 2B) but similar between the two groups at 4 weeks
post-MI (Figure 2B), indicating that this reduction in post-
MI apoptosis induced by βARKct is short-lived. As
for post-MI cardiac inflammation in the two animal
groups, levels of the major pro-inflammatory cytokines
TNFα(Figure 2C), IL-6 (Figure 2D) and IL-1β (Figure 2E)
are significantly increased in the hearts of βARKct/B1KO
mice, compared to control B1KO hearts at 24 hrs post-MI,
indicating increased wound (infarct) healing-associated in-
flammation. By 4 weeks post-MI however, levels of all these
three cytokines (TNFα, IL-6, IL-1β) in βARKct/B1KO
hearts have returned to the levels of 24-hour post-MI
B1KO hearts (data not shown), indicating that also the ef-
fect of βARKct on post-MI inflammation is short-lived.
To identify potential signaling mechanisms underlying
these effects of βARKct on apoptosis and inflammation
Figure 1 β2AR-PDE4D interaction in the heart. Co-immunoprecipitation (co-IP) followed by western blotting in cardiac extracts from normal
(sham) B1KO and βARKct/B1KO (CT/B1KO) mice to measure the β2AR-PDE4D interaction in the heart. Representative immunoblots are shown in
(A), and the amounts of the co-immunoprecipitated PDE4D isoforms, as measured by densitometry and normalized with the amount of β2AR
pulled down in the co-IP, are shown in (B). *, p<0.05, vs. B1KO; n=4 independent experiments (i.e. performed on 4 different hearts from each
mouse line). IP: Immunoprecipitation, IB: Immunoblotting.
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the major anti-apoptotic mediator Bcl-2 [37] and levels
of activation of the crucial pro-inflammatory transcrip-
tion factor NFκB. Bcl-2 was found significantly up-
regulated in βARKct/B1KO hearts compared to control
B1KO hearts at 24 hrs post-MI (Figures 3A and 3B), in-
dicating enhanced cellular survival/inhibition of apop-
tosis. However, at 4 weeks post-MI, Bcl-2 protein was
virtually undetectable in the hearts of both mouse lines
(Figure 3C), which is consistent with the phenotypic
finding of the short-lived inhibition of apoptosis in the
heart by βARKct (Figure 2B). In addition, NFκB activa-
tion appears also markedly elevated in βARKct/B1KO
hearts compared to control B1KO hearts at 24 hrs post-
MI (Figures 3A and 3B), indicating enhanced cardiac in-
flammation. For NFκB to get activated, its inhibitory
IκBα subunit must be phosphorylated and subsequently
targeted for proteasomal degradation to release the tran-
scriptionally active subunits of the complex [28-30].
Thus, increased phosphorylation of IκBα and decreased
levels (increased degradation) of total IκBα in the hybridtransgenic hearts at 24 hrs post-MI (Figures 3A and 3B)
suggest increased NFκB activation compared to B1KO
hearts. Finally, blotting for βARKct in these hearts con-
firmed the robust expression of this GRK2 inhibitor in
the hearts of βARKct/B1KO’s, which, of course, was ab-
sent from the hearts of B1KO mice (Figure 3A).GRK5 and cardiac β2AR-dependent signaling
Apart from GRK2, the other major cardiac GRK that
can phosphorylate and desensitize β2ARs, and thus op-
pose β2AR pro-contractile and anti-apoptotic signaling,
is GRK5 [8-10]. As shown in Figure 3D, cardiac post-MI
GRK5 levels are initially (at 24 hrs post-MI) similar be-
tween the two groups, as is the case also in the healthy,
sham-operated groups (data not shown). By 4 weeks
post-MI however, a significant up-regulation (~2-fold
increase) of GRK5 is observed in βARKct/B1KO hearts
compared to control B1KO hearts (Figure 3D), indicat-
ing that GRK2 inhibition with βARKct leads to a com-
pensatory up-regulation of GRK5 over time.
Figure 2 (See legend on next page.)
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Figure 2 Survival, cardiac apoptosis and inflammation post-MI. (A) Kaplan-Meier survival curves of the 4 groups of mice of the study:
sham-operated (Sham) and post-MI (MI) B1KO and βARKct/B1KO mice. p=0.011 between MI B1KO and MI βARKct/B1KO; n=15 mice/group for sham,
37 mice/group for MI mice. (B) Apoptotic cell death at 24 hrs and at 4 weeks (wks) post-MI in the two transgenic (B1KO and CT/B1KO) lines, as
measured by TUNEL performed in the border zone of the infarct. No difference in rate of apoptosis in the remote zone at either post-MI time point
was found (data not shown). **, p<0.05, vs. B1KO 24 hrs, n=6 mice/group. (C-E) Levels of pro-inflammatory cytokines TNFα (C), IL-6 (D), and IL-1β (E),
measured via ELISA in serum of intra-cardiac blood from B1KO and βARKct/B1KO (CT/B1KO) mice at 24 hrs post-MI. *, p<0.05, n=5 mice/group.
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The present study reports for the first time, to our
knowledge, that cardiac GRK2 is an endogenous “stum-
bling block” that normally prevents β2AR signaling from
stimulating contractility, mainly because it promotesFigure 3 Levels of cardiac Bcl-2, NFκB activity and GRK5 post-MI. (A-B
and βARKct/B1KO (CT/B1KO) mice for βARKct, Bcl-2, phospho-IκBα (pIκBα),
for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as loading contro
with GAPDH as control and expressed as % of B1KO levels, of 4 independe
(C) Western blotting for Bcl-2 protein in total cardiac extracts from 4 week
from 4 independent experiments done in duplicate are shown, including G
(input) for Bcl-2. Bcl-2 was virtually undetectable in either group at 4 weeks
B1KO and βARKct/B1KO (CT/KO) mice at 24 hrs and at 4 weeks (wks) post-
duplicate, with GAPDH as loading control, are shown on top, and densitomassociation of this βAR subtype with PDE4D in the
heart, a major molecular “brake” on cardiac β2AR-
dependent contractility [6,7,15]. Thus, only when cardiac
GRK2 is blocked (e.g. with βARKct) is the β2AR capable
of promoting cardiac contractility. Obviously, several) Western blotting in total cardiac extracts from 24 hr post-MI B1KO
and total IκBα. Representative blots are shown in (A), including blots
l for each protein tested, and densitometric quantitation, normalized
nt experiments done in duplicate, is shown in (B). *, p<0.05, vs. B1KO.
post-MI B1KO and βARKct/B1KO (CT/B1KO) mice. Representative blots
APDH as loading control and h9c2 cell extract as positive control
post-MI. (D) Western blotting for GRK5 in total cardiac extracts from
MI. Representative blots of 4 independent experiments done in
etric quantitation on bottom. *, p<0.05, vs. all other groups.
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sent study has identified the following two: 1) βARKct, by
blocking GRK2, reduces the uncoupling of β2AR with
the classical pro-contractile Gs protein-adenylyl cyclase-
cAMP-PKA signaling pathway (Figure 4), and 2) GRK2
blockade reduces the interaction of β2AR with βarrs,
which scaffold on themselves various isoforms of PDE4D
(mainly PDE4D3 and PDE4D5) (Figure 4). PDE4D causes
degradation of the local cAMP signals produced by
activated β2AR, which are essential for stimulation of
contractility, and thus it weakens these pro-contractile
signals hampering β2AR-stimulated contractility [6,7,15].
By indirectly reducing the βarr-PDE4D interaction
with the cardiac β2AR, βARKct releases the “brake”
PDE4D poses on this receptor’s pro-contractile signal-
ing and enhances its capacity to stimulate contractility
(Figure 4).Figure 4 Schematic illustration of the signaling pathways discussed in
myocytes and are affected by GRK2 inhibition with βARKct. CA: Catec
for details and all other molecular acronym descriptions.Since the other major beneficial effect of cardiac β2AR
signaling in vivo is inhibition of apoptosis (promotion of
survival), we also tested the effects of cardiac GRK2
blockade in vivo on this aspect of β2AR signaling in the
context of post-MI HF progression. We found that early
on after MI, cardiac GRK2 blockade with βARKct also
dramatically augments β2AR anti-apoptotic signaling, as
well as its pro-infarct healing inflammatory signaling, in
the heart. This results in significant reduction in all-
cause mortality (marked increase in animal survival in
the first 4 weeks post-MI), and reduced cellular apop-
tosis in the post-MI heart, compared to B1KO mice with
unopposed cardiac GRK2 activity. Thus, βARKct en-
hances not only cardiac contractility, but also cardiac
survival stimulated by the β2AR, which further rein-
forces its validity as an attractive therapeutic strategy to
potentiate cardiac β2AR signaling and function in post-MIthe present study that are elicited by β2AR activation in cardiac
holamine; AC: Adenylyl cyclase; ATP: adenosine triphosphate. See text
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of other cardio-protective receptors that are also GRK2
substrates by βARKct cannot be ruled out and is, in fact,
quite likely to have contributed to the observed cardiac
apoptosis phenotype of βARKct/B1KO mice. However,
βARKct’s cardio-protective and anti-apoptotic effects have
been shown to be β2AR-dependent, since selective block-
ade of this receptor in cardiac myocytes abolishes βARKct-
mediated anti-apoptotic effects [38]. On the other hand,
effects of βARKct on β2AR-dependent pro-angiogenetic
signaling, which plays an important role in peri-infarct HF
progression [39], cannot be ruled out either. Nevertheless,
it becomes quite clear from our current data that βARKct
augments β2AR contractile function without negatively af-
fecting its anti-apoptotic one, but rather actually preserving
and further enhancing this β2AR function, as well.
However, this augmentation of anti-apoptotic signaling
is short-lived: by 4 weeks post-MI, cardiac cellular apop-
tosis has returned to the 24-hour post-MI B1KO heart
levels. This might be related to the nature of cardiac β2AR
pro-survival signaling; β2AR can have remarkably different
effects in the heart depending on its expression levels and
on time [40,41]. Cardiac β2AR is known to be beneficial
(i.e. promoting survival) at low levels of overexpression
and in the first few months of life in mice, but when
overexpressed at extremely high levels in murine hearts or
later on in the mouse’s life, these animals do not survive
and die of severe cardiac complications [40]. Mechanistic-
ally, cardiac β2AR anti-apoptotic signaling is known to
proceed mainly through the Gi/o protein signaling pathway
[20-23], to which it is capable of switching following its
phosphorylation by PKA [42]. GRK2 blockade by βARKct
can increase this signaling by a) decreasing the pathway’s
βarr-mediated desensitization, i.e. increasing the coupling
of Gi/o proteins with the β2AR, and b) by increasing the
PKA-dependent switching of β2AR signaling from Gs to
Gi/o proteins thanks to the increase of β2AR signaling via
the Gs protein-cAMP-PKA (the pro-contractile) pathway
it also causes, discussed above (Figure 4). With regards to
the pro-inflammatory signaling of cardiac β2AR, βarrs are
known to scaffold and stabilize the inhibitory IκBα subunit
of NFκB, thereby prohibiting NFκB activation [26,27].
GRK2 blockade with βARKct decreases βarr interaction
with the β2AR thereby “releasing” the inhibitory effect of
βarrs on NFκB activation (Figure 4). Thus, NFκB activa-
tion and the subsequent pro-inflammatory cytokine pro-
duction are enhanced (Figure 4). Indeed, NFκB activation
and inflammatory cytokine levels were found significantly
elevated in βARKct/B1KO hearts compared to B1KO
hearts without GRK2 inhibition at 24 hrs post-MI.
Meanwhile however, βARKct also causes upregulation
of the other major cardiac GRK, GRK5, in the first few
weeks post-MI. This is also probably due to the enhanced
NFκB activation (Figure 4), since NFκB can causeupregulation of GRK5 in cardiomyocytes [43]. Import-
antly, and given that GRK5 elevation is generally consid-
ered detrimental for the heart [8-10], this finding might
explain, at least in part, the aforementioned switching of
cardiac β2AR signaling from beneficial (anti-apoptotic)
early in life of transgenic mice or at low levels of receptor
expression to detrimental (pro-apoptotic) later on in the
lifespan of these mice or at very high levels of cardiac
β2AR overexpression [41]. Of note, GRK5 has also been
reported to bind (via its non-catalytic, N-terminal domain)
to, and stabilize IκBα, thereby inhibiting NFκB activity in
several tissues, including the heart [44]. Therefore, our
present findings strongly indicate that a negative feedback
loop might exist in the heart, in which NFκB induces
GRK5 expression, and GRK5 can subsequently suppress
NFκB activation (Figure 4).
Conclusions
In summary, the present study reports that cardiac
GRK2 inhibition with βARKct in vivo is absolutely es-
sential for the cardiac β2AR subtype’s pro-contractile
function, all the while preserving and augmenting this
receptor’s beneficial anti-apoptotic/pro-survival and pro-
infarct healing signaling pathways post-MI, early on after
the cardiac insult. However, the effects of βARKct on
the latter signaling modalities are transient due (in part)
to compensatory elevation of cardiac GRK5 over time.
Methods
Experimental animals and surgical procedures
The animals in this study were handled according to ani-
mal welfare regulations and protocols approved by the au-
thors’ Institutional Review Boards. Genetically engineered,
8- to 12-wk-old β1AR KO (B1KO) (on C57/B6 back-
ground) [36] and the offspring of their cross with Mini-27
mice, expressing the βARKct (or GRK2ct) transgene under
the alpha-myosin heavy chain gene promoter [32], were
used for this study. Mice were anesthetized with a mixture
of ketamine (100 mg/kg) and xylazine (2.5 mg/kg). Ani-
mals were placed in the supine position on a heated oper-
ation board and a midline cervical incision was made to
expose the trachea. Following successful endotracheal
intubation, the cannula was connected to a rodent ventila-
tor. The entire left ventricle (i.e. both infarct and non-
infarct zones) were used for subsequent histological and
biochemical assays. Myocardial infarction was performed
as previously described [35].
Echocardiography & in vivo hemodynamics
Transthoracic echocardiography was performed with a
linear 30-MHz transducer (VeVo 770 High Resolution
Imaging System, VisualSonics, Toronto, ON, Canada), as
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performed as previously described [35].
In situ TUNEL staining
Heart specimens were fixed with 10% neutral buffered
formalin, embedded in paraffin, and sectioned at 5-μm
thickness. DNA fragmentation was detected in situ in
deparaffinized sections using the ApopTag Kit (Intergene)
and according to manufacturer’s instructions, as described
previously [45]. The total number of nuclei was deter-
mined by manual counting of DAPI-stained nuclei in six
random fields per section. All terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL)-
positive nuclei were counted in each section.
Co-immunoprecipitation and western blotting
Cardiac extracts were prepared in 20 mM Tris pH 7.4,
137 mM NaCl, 1% Nonidet P-40, 20% glycerol, 10 mM
PMSF, 1 mM Na3VO4, 10 mM NaF, 2.5 μg/ml aprotinin,
and 2.5 μg/ml leupeptin. Protein concentration was then
determined and equal amounts of protein per sample were
loaded on SDS-PAGE gels for electrophoretic separation,
as described previously [46]. For β2AR-PDE4D co-
immunoprecipitation experiments, β2AR was immuno-
precipitated with an anti-mouse β2AR antibody (sc-9042,
Santa Cruz), immobilized on Protein A-sepharose beads
(Invitrogen), prior to SDS-PAGE/western blotting. Total
IκBα and phospho-IκBα were detected by using anti-IκBα
(sc-1643, Santa Cruz) and anti-phosphoIκBα at Ser-32
(sc-7977, Santa Cruz) antibodies, Bcl-2, GRK5, GRK2/
βARKct and GAPDH, with antibodies sc-492, sc-565,
sc-562, and sc-25778, respectively (all from Santa Cruz),
and PDE4D (various isoforms) with the PD4-401AP
antibody (FabGennix). Immunoblots were revealed by
enhanced chemiluminescence (ECL, Amersham Biosci-
ences) and visualized in the FluorChem E Digital Dark-
room (Cell Biosciences). Densitometry was performed
with the AlphaView software (Cell Biosciences) in the lin-
ear range of signal detection (on non-saturated bands).
Cytokine measurements via ELISA
Pro-inflammatory cytokines TNFα, IL-6 and IL-1β were
measured in serum obtained from left ventricular blood,
immediately prior to heart excision and animal euthaniz-
ing, via multiplexed ELISA, as described [47,48]. The
assay was performed using the Mouse Cytokine ELISA
Profiling Kit (EA-1091, Signosis), according to the man-
ufacturer’s instructions.
Statistical analyses
Data are generally expressed as mean ± SEM. Unpaired 2-
tailed Student’s t test and one- or two-way ANOVA with
Bonferroni test were generally performed for statisticalcomparisons, unless otherwise indicated. For all tests, a
p value of <0.05 was generally considered to be significant.
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